Skip to main content

Value Stock - Dividend - Research Selection

ISIN: , WKN:

Market price date:
Market price:  


Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Ratios
Key figures
Cash flow
P/C
 
P/FC
Balance sheet
ROI
ROE
Income statement
P/E
Div. Yield%
P/B
P/S


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



DescriptionData
Symbol
Market Capitalization USD
Country
Indices
Sectors
Raw Data Source
Stock Split
Internet


Description of the company

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov,


NEWS


Clinuvel Pharmaceuticals Limited's (ASX:CUV) Stock Has Fared Decently: Is the Market Following Strong Financials?

2022-11-23
Most readers would already know that Clinuvel Pharmaceuticals' (ASX:CUV) stock increased by 4.1% over the past three...

While institutions own 21% of Clinuvel Pharmaceuticals Limited (ASX:CUV), individual investors are its largest shareholders with 54% ownership

2022-11-07
If you want to know who really controls Clinuvel Pharmaceuticals Limited ( ASX:CUV ), then you'll have to look at the...

Clinuvel Pharmaceuticals Limited's (ASX:CUV) CEO Compensation Is Looking A Bit Stretched At The Moment

2022-10-20
The underwhelming share price performance of Clinuvel Pharmaceuticals Limited ( ASX:CUV ) in the past three years would...

Clinuvel Pharmaceuticals' (ASX:CUV) earnings growth rate lags the 25% CAGR delivered to shareholders

2022-09-19
It's been a soft week for Clinuvel Pharmaceuticals Limited ( ASX:CUV ) shares, which are down 14%. But that scarcely...